论文部分内容阅读
目的评估胱抑素C在阿托伐他汀治疗糖尿病早期肾损伤中的价值。方法血清胱抑素C和尿微量白蛋白采用免疫比浊法检测,血肌酐检测采用碱性苦味酸速率法。选取血糖控制达标的糖尿病肾病2～3期患者80例,随机分成两组,对照组未使用阿托伐他汀,治疗组给予阿托伐他汀40 mg/d,连续治疗16周后,分别检测两组患者的血清光抑素C、尿微量白蛋白、血肌酐。评估阿托伐他汀治疗的糖尿病患者的早期肾损伤。结果两组治疗前比较差异无统计学意义(P>0.05);但治疗组经阿托伐他汀治疗16周后,尿微量白蛋白、血肌酐、血清光抑素C明显下降,与治疗前水平比较差异有统计学意义(P<0.05),两组治疗后水平比较差异亦有统计学意义(P<0.05)。结论阿托伐他汀能降低糖尿病患者的早期肾功能损害,在这些肾功能损害指标中胱抑素C水平与血肌酐、尿微量白蛋白有很好的相关性,血清胱抑素C能较好地反映肾小球滤过率,是糖尿病肾病早期损害的敏感指标。
Objective To assess the value of cystatin C in the treatment of early diabetic renal damage with atorvastatin. Methods Serum cystatin C and urine microalbumin were detected by immunoturbidimetry and serum creatinine was detected by alkaline picric acid rate method. Eighty patients with diabetic nephropathy who achieved the goal of glycemic control were randomly divided into two groups. Atorvastatin was not used in the control group. Atorvastatin 40 mg / d was given to the treatment group. After continuous treatment for 16 weeks, Group of patients with serum phototensin C, urinary albumin, serum creatinine. Assess early renal impairment in atorvastatin-treated diabetic patients. Results There was no significant difference between the two groups before treatment (P> 0.05). However, after treatment with atorvastatin for 16 weeks in the treatment group, urinary albumin, serum creatinine and serum phototensin C were significantly decreased, The difference was statistically significant (P <0.05). There was also significant difference between the two groups after treatment (P <0.05). Conclusions Atorvastatin can reduce the early renal dysfunction in diabetic patients. Cystatin C levels correlate well with serum creatinine and urinary albumin in these indicators of renal impairment, and serum cystatin C can be better To reflect the glomerular filtration rate, is a sensitive indicator of early damage of diabetic nephropathy.